Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer | OncLive

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20, 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

The vaccine, called Stimuvax, was compared with placebo as maintenance therapy following chemoradiation. The primary endpoint, overall survival, was not met in the intent-to-treat population.

In patients who received concurrent chemoradiation saw a 10-month survival benefit when treated with the vaccine. Piperdi says more research is planned in this space.


x